International Conference on “Neurotrophic Factors and Neurodegenerative Disorders; Current Advances and Future Perspectives”
We kindly invite you to the conference entitled “Neurotrophic Factors and Neurodegenerative Disorders; Current Advances and Future Perspectives” that will be organised in the context of the “EuroNeurotrophin” project by FORTH, in Crete, on August 27th-29th 2021.
The Conference will be delivered as a virtual event and registration is free of charge.
Neurodegenerative diseases (ND), like Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis and motor neuron disease, are on the rise worldwide. Alzheimer’s disease alone affects 36 million people in the world and 7 million in Europe. The economic burden for ND exceeds 724 billion € and it will become a trillion euros by 2019. Currently, there is no cure for any ND and most of the available drugs fail to tackle ND pathogenesis.
Neurotrophins are a family of closely related secreted proteins that have been shown to control a number of aspects of survival, development and function of neurons both in the central and the peripheral nervous systems.
Preclinical studies point to the therapeutic potential of neurotrophins in preventing or slowing the progression of ND. Thus, neurotrophins have been proposed as therapeutic agents for neurodegenerative diseases.
However, the poor pharmacokinetic properties of neurotrophins, mainly because of their sensitivity to proteolysis, restricted penetration of the blood–brain barrier, and limited ability to diffuse in tissues, render their use as drugs prohibitive.
The EuroNeurotrophin project aims to address the major limitations of neurotrophins by developing novel small molecule, neurotrophin mimetics with favourable profiles of stability, tissue penetration and targeted biological actions.
The EuroNeurotrophin project is the first European consortium to study small molecule neurotrophin mimetics (synthetic or natural) in depth, use them as molecular probes to interrogate neurotrophins, and emphasise their clinical translation.
Visit the conference page to register and for more details.
We look forward to seeing you online in August!
Susanne Kohout, the Country President and Managing Director of our EuroNeurotrophin Partner Organisation, Novartis (Hellas) S.A.C.I. in Greece held an interview with Fortune Greece on Novartis’ mission to help people live longer and better.
In the interview, Susanne Kohout tells us about her background and the development of the organisation and its strong position in the global market and how it got there. She also raises the concerns and challenges the COVID-19 pandemic has brought to Greece and the company itself and how they are handling this situation.
The full article is available to read online on fortunegreece.com
Novartis is ranked amongst one of the companies most heavily investing in R&D globally and we are happy to have them involved in the EuroNeurotrophin Project.
Alessia Latorrata (ESR2) presented the research from her individual research project during the Synthesis in Drug Discovery and Development Virtual Symposium, 22.-23. March. Her poster titled ”Synthesis of new DHEA 17-spyro-cyclopropyl derivatives with Neurotrophic, Neuroprotective and Anti-Inflammatory activity” was presented during the virtual poster sessions to chemists from industry and academia, including synthetic, medicinal and process chemists.
At the Journées de l'Ecole Doctorale Normande de Chimie 2020, ESR6 Mirjana Antonijević won with her presentation the best oral communication prize. The meeting was held online on the 27/28. November 2020.
JEDNC is an annual meeting organized by PhD students and for PhD students of the Normandy University which includes three universities: the University of Rouen, the University of Le Havre and the University of Caen. This congress enables PhD students to share their research work, in different fields and with professionals from academia and industry.
Mirjana Antonijević won with her presentation about "Multi-target neurotrophin receptors ligands, an emerging strategy in the treatment of neurodegenerative diseases".
Award-winning Sheffield neuroscientists honoured at Buckingham Palace reception
The prize awarded to the University of Sheffield recognises the work that the Sheffield Institute for Translational Neuroscience (SITraN) at the University does to improve patient outcomes for people living with some of the most devastating neurodegenerative diseases.
Achievements highlighted by the award included:
The prize is unique in the UK honours system, as it is only bestowed upon a UK college or university which demonstrates new and unique innovative approaches to its research.
Professor Dame Pamela Shaw, Director of SITraN and the NIHR Sheffield Biomedical Research Centre, said: “This prize recognises the University of Sheffield as a centre for excellence in neuroscience research and teaching, where our researchers are making lifechanging discoveries and progress in treating some of the most devastating neurological diseases, making a real difference to patients’ lives.
“As well as making life-changing discoveries today, we are also nurturing the next generation of talented neuroscience students, whose research will lead to pioneering treatments for those living with neurological diseases in the future. This includes the Euroneurotrophin PhD Studentship programme with colleagues from several European countries”
“We hope this award will help inspire confidence in patients and their families, research
partners and donors, as we continue to make discoveries that deepen the understanding of
neurological diseases and open up the potential for new treatments and therapies.”
SITraN’s vision is to harness the rapidly emerging, exciting developments in neuroscience to
translate into new treatments and improved quality of life for patients with neurodegenerative disorders such as Parkinson’s Disease, MND, Alzheimer’s Disease, MS and Dementia.
The centre - considered a world-leader in neuroscience research - will celebrate its 10th anniversary this year. Its work forms part of the University of Sheffield’s Neuroscience Institute, which aims to bring academics together from across medicine, science and engineering to translate scientific discoveries from the lab into pioneering new treatments.
Sir Damon Buffini, Chairman of the Royal Anniversary Trust, said: “It has been fantastic to celebrate the 13th Round of Prize-winners at Buckingham Palace alongside TRH Prince of Wales and the Duchess of Cornwall. The Royal Anniversary Trust showcased the exceptional, innovative and impactful work of our colleges and universities throughout the UK. We look forward to seeing how the work develops and progresses over the coming years!”